Leucid Bio raises GBP11.5m in Series A financing
Leucid Bio (Leucid), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, has successfully raised GBP11.5 million in a Series A financing round. The investment was led by Epidarex and new investor Vulpes Investment Management, with participation from new investors 2Invest and Future Fund of the British Business Bank,